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Organ transplantation is useful for treating the end stage of organ failure. The induction
of tolerance to the transplanted organ is essential for its long-term survival. Immunologic
tolerance can be induced by immunosuppressive agents and mixed chimerism. Mixed
chimerism is a state in which both recipient-and donor-derived blood cells remain in the
hematopoietic system after allogeneic hematopoietic stem cells have been transplanted.
Mesenchymal stem cells (MSCs), and immune cells such as dendritic cells and T-reg
cells play an important role in the induction of tolerance. MSCs secrete cytokines, which
modulate the immune response. In particular, they upregulate T-reg cell function and
thereby induce tolerance. Intra-bone marrow-bone marrow transplantation recruits both
donor-derived HSCs and MSCs, inducing persistent donor-specific tolerance without the
use of immunosuppressants. In this review, we summarize the use of MSCs to induce
tolerance in organ transplantation.
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INTRODUCTION
Organ transplantation is useful for treating the end stage of
organ failure, but it is imperative that stable tolerance is induced
in the recipients in order for the transplanted organ to sur-
vive long term. The induction of immunological tolerance to
organ transplants can be categorized into the use of immuno-
suppressive agents to modulate T cell and B cell agents and the
use of cellular therapies such as mixed chimerism (Salisbury
et al., 2013). Immunosuppressive agents have been used to pre-
vent an immune response in the host and the acute rejection of
the transplanted organ. However, the side effects of non-specific
immunosuppressive agents include not only the risk of infec-
tion but also the inability to prevent the chronic rejection of
the transplanted organ (Ildstad et al., 2011). Mixed chimerism,
which can be established by the transplantation of hematopoi-
etic stem cells (HSCs), has been shown to be a better method of
inducing tolerance in organ transplantation. In clinical practice,
organ transplantation using a conditioning regimen consisting
of total lymphoid irradiation plus immunosuppressants such as
cyclophosphamide (CYP) and fludarabine has been shown to
induce mixed chimerism (Sachs et al., 2014). One case report
describes how a patient who received CD34+ cells (8× 106/kg
body weight) on day14 after kidney transplantation, showed
neither kidney rejection nor clinical manifestations of graft-
versus-host disease (GVHD) during a follow-up for of more
than 2 years (Scandling et al., 2008). Another review summarizes
the induction of long-term allograft tolerance through mixed
chimerism in small and large animal models, and includes clinical
studies (Sachs et al., 2011). Allogeneic chimerism and tolerance
have been induced by HSC transplantation in human leukocyte
antigen-mismatched patients when kidneys were transplanted—
without any evidence of acute GVHD in the recipients. And
stable renal function was maintained as a result of the persistent
donor chimerism without the use of immunosuppressive agents
(Leventhal et al., 2012). Immune cells such as regulatory T (T-reg)
cells, immature dendritic cells (DCs), and mesenchymal stem
cells (MSCs) play important roles in the induction of immune
tolerance in organ transplantation (Wood et al., 2012). Recent
reports have suggested that MSC-derived-exosomes, which are
released by exocytosis with the plasma membrane, may benefit
therapy-refractory GvHD patients. The use of MSC exosomes,
being-the therapeutically active component of MSCs, provides a
number of advantages compared to just MSCs (Kordelas et al.,
2014).
IMMUNE TOLERANCE
Immune tolerance includes central tolerance, which occurs in the
thymus, and peripheral tolerance, which includes the deletion of
effector T cells and the induction of expansion of active T-reg
cells (Wood and Sakaguchi, 2003). In central tolerance, T cell
precursors from the bone marrow (BM) enter the thymus and
are selected by thymic epithelial cells via positive and negative
selection. These selected T cells show tolerance to autoanti-
gens when they enter peripheral lymphoid tissues. Peripheral
tolerance includes the induction of anergy, and the active regu-
lation of effector T cells. Immature DCs, T reg cells and MSCs
play an important role in the induction of peripheral toler-
ance. BM-derived immature DCs express low MHC class II and
co-stimulatory molecules to promote tolerance to solid organ
allografts, and the injection of donor-derived DCs may prevent
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the rejection ofMHC-mismatched skin grafts (Roelen et al., 2003;
van Kooten et al., 2011).
The markers of T-reg cells, CD4, CD25, and FoxP3, mainly
mature in the thymus. The presence of T-reg cells has been
reported to reduce the need for conditioning regimens in the
generation of mixed chimerism (Raimondi et al., 2010),being
the presence of both donor- and recipient-derived hematopoi-
etic cells in the recipients after BM transplantation (BMT) (Pilat
and Wekerle, 2010). It has been shown that mixed chimerism
is more effective than full chimerism in combating infectious
risk when allogeneic kidney transplants were performed in
humans, with non-myeloablative conditioning promoting the
mixed chimerism and helping the renal allografts to survive
(Buhler et al., 2002; Kawai et al., 2011).MSCs can be isolated from
many tissues, and not only support the growth of hematopoi-
etic stem cells (HSCs), but also secrete cytokines to regulate
the immune response. Human MSCs promote the generation of
CD4+CD25+FoxP3+T-reg cells, and induce tolerance to allo-
grafts (Casiraghi et al., 2008; English et al., 2009). Moreover,
MSCs secrete matrix metalloproteinases (MMP), protect allo-
geneic islets, and maintain long-term normoglycemia through
MMP-2 and -9 in vitro (Ding et al., 2009).
MSCs INDUCE TOLERANCE IN ORGAN TRANSPLANTATION
The functions of MSCs and their effects on immune cells have
been summarized in two reviews (Uccelli et al., 2008; Li and
Ikehara, 2013). MSCs suppress allogeneic T cell responses by
secreting soluble factors such as PGE2, IL-10, and IL-6 (English,
2013), and modulate DC function, indirectly regulate T and B cell
activity, delay and prevent the development of GVHD and sup-
press DC function (Zhang et al., 2009; Aldinucci et al., 2010).
MSCs have been shown to alter the NK cell phenotype and
suppress proliferation, decrease cytokine levels such as those of
TNFα, IFNγ and IL-12, and increase IL-10. One report has shown
that porcine MSCs inhibit alloreactive T cells through the induc-
tion of PGE2 and indoleamine 2,3-dioxygenase (IDO) (Hsu et al.,
2013).
The immunoregulatory properties of MSCs have been
reported in vitro and in vivo. MSCs suppress T-cell responses,
inducing tolerance to transplanted kidney via the expression of
IDO (Ge et al., 2010). An infusion of MSCs and rapamycin has
been shown to induce heart allograft-specific tolerance, support-
ing the idea that MSCs might be used for inducing tolerance
in a clinical setting (Ge et al., 2009). The MSC infusion leads
to an expansion of T-reg cells and prolongs allograft survival
in a MHC matched heterotopic heart transplantation model.
Moreover, MSC infusion is characterized by reduced numbers
of Th1 effector cells (Casiraghi et al., 2008). However, there
is one report indicating that donor-specific MSC pre-treatment
resulted in a higher degree of kidney cortex tissue damage and
elevated creatinine levels in a rat kidney transplantation model
(Seifert et al., 2012). Another report showed that MSCs sup-
pressed allogeneic T-cell responses and prolonged the survival
of transplanted hearts by improving the Th1/Th2 balance when
allogeneic heart transplantation was combined with the intra-
venous infusion of MSCs (Zhou et al., 2006). Transplanted MSCs
may promote revascularization and improve islet graft function
after the co-transplantation of islets withMSCs in streptozotocin-
induced diabetic rats (Ito et al., 2010).
In clinical trials, intravenous infusions of autologous BM-
derived MSCs were given to kidney allograft recipients. Although
immunosuppression remained unaltered, there was a resolution
of tubulitis without interstitial fibrosis/tubular atrophy in one
third of patients. Additionally, five of the six patients displayed
a donor-specific downregulation of peripheral blood mononu-
clear cell proliferation, which was not reported in patients that
did not have the MSC treatment. These results suggest that autol-
ogous BM-derived MSC treatment provides systemic immuno-
suppression in allograft transplantation (Reinders et al., 2013).
Calcineurin inhibitors (CNIs) have been reported to reduce
acute rejection rates in kidney recipients. The infusion of MSCs
combined with CNIs improved renal function such as the esti-
mated glomerular filtration rate at the first month after treat-
ment. This therapy decreased the incidence of acute rejection,
and also decreased the risk of opportunistic infection at 1
year after treatment (Tan et al., 2012). Infusion of MSCs was
used for the treatment of patients who received kidney trans-
plants, and these infused MSCs increased the percentage of
CD4+CD25+FoxP3+CD127- T-reg cells and decreased mem-
ory T cells, and CD8+ T cell activity. The infusion of MSCs thus
appears to be a safe and clinically feasible method for patients
receiving organ transplants (Perico et al., 2011). BM-derived
MSCs have been used clinically to treat GVHD, decrease the risk
of infection, and help induce tolerance in organ transplantation,
and one review indicates that MSCs promote tolerance in the case
of kidney transplants (Casiraghi et al., 2014).
WhenMSCs are infused by intravenous injection, they become
trapped in the lungs and other tissues, and it is therefore prefer-
able for the MSCs to be directly injected into the bone cavity.
Intra-bone marrow-BMT (IBM-BMT) has been shown to effi-
ciently recruit not only donor-derived HSCs but also MSCs in
animal experiments (Fukui et al., 2007; Guo et al., 2008; Song
et al., 2008). Furthermore, IBM-BMT induced tolerance to adult
allogeneic liver in mice (Okazaki et al., 2008). IBM-BMT is a
feasible strategy for the induction of persistent donor-specific tol-
erance, enables the use of reduced radiation doses as conditioning
FIGURE 1 | MSCs induce tolerance in organ transplantation.
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regimens, and obviates the need for immunosuppressants (Guo
et al., 2008). IBM-BMT induced tolerance in the case of allogeneic
lung transplants, while intravenous BMT failed to do so (Kaneda
et al., 2005). HSCs can normally proliferate in major histocom-
patibility complex (MHC)-compatible MSCs even in allogeneic
microenvironments.
In conclusion, MSCs have been shown to prevent GVHD, and
to induce tolerance in organ transplantation in both animal and
clinical studies (Figure 1). MSCs can be easily isolated from bone
marrow and adipose tissue, and their use thus represents a feasible
approach in the clinical setting for inducing tolerance in organ
transplantation.
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